Record mula sa primary source

MateryalPagbabago sa trial registry

Surrozen doses first patient in Phase 1b DUET study of SZN-8141 in DME; expands Phase 2a to 150 patients

Surrozen dosed the first patient in the open-label Phase 1b single-ascending-dose portion of the DUET study of SZN-8141 in DME patients. The company is expanding the randomized Phase 2a portion from ~60 to 150 patients to evaluate two dose levels versus Vabysmo in treatment-naive and experienced patients. Topline data from Phase 1b is now expected in H2 2027 and Phase 2a in 2028.

Mahahalagang fact

Na-file
Nob 9, 2026, 09:18 PM
Kaganapan
Pagbabago sa trial registry
Direksyon
Neutral
Pinagmulan
SEC 8-K
Kumpiyansa
May source
enrollment ng phase 2a
150
orihinal na enrollment ng phase 2a
60

Sipi mula sa source

EX-99.1 2 srzn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update First patient dosed in Phase 1b of DUET study evaluating SZN-8141 in patients with diabetic macular edema DUET Phase 2a enrollment to be expanded from approximately 60 to 150 patients to enable a more robust evaluation of SZN-8141 in DME Topline data from DUET Phase 1b expected in second half of 2027; Phase 2a topline data expected in 2028 Second tranche of March 2025 PIPE and ATM transaction totaling approximately $118.9 million in net proceeds in October 2026 extend anticipated cash runway into 2029 SOUTH SAN FRANCISCO, Calif., November 09, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company

SEC 8-K

Higit pa tungkol sa asset na ito

Okt 20, 2026
09:04 PM
SRZNSurrozen

Isinara ni Surrozen ang $95.1M na Tranche ng Private Placement Pagkatapos ng IND Clearance para sa SZN-8141

Pagbabago sa trial registrySEC 8-K
Okt 2, 2026
12:05 PM
SRZNSurrozen

Natanggap ng Surrozen ang Clearance ng FDA IND para sa SZN-8141 sa DME

Iba paSEC 8-K
May 6, 2026
08:15 PM
SRZNSurrozen

Plano ng Surrozen na isumite ang IND para sa SZN-8141 sa H2 2026

Pagbabago sa trial registrySEC 8-K
Mar 23, 2026
08:16 PM
SRZNSurrozen

Plano ng Surrozen na magsumite ng IND para sa SZN-8141 sa H2 2026

Pagbabago sa trial registrySEC 8-K
Surrozen doses first patient in Phase 1b DUET study of SZN-8141 in DME; expands Phase 2a to 150 patients | SimianX AI